Welcome! Login | Register

Blizzard Juno Hits Scituate—Blizzard Juno Hits Scituate

Blizzard Juno Hits The East Side and Pawtucket—Blizzard Juno Hits The East Side and Pawtucket

Blizzard Juno Hits Newport—Blizzard Juno hits Newport

Lifespan’s Closings and Cancellations in Anticipation of Juno—Lifespan health system has cancelled all outpatient procedures,…

Organize + Energize: 5 Reasons Paper Clutter Forms—You know if you have paper management issues.

Robert Kraft Addresses Deflategate In Surprise Press Conference—Patriots Chairman & CEO Robert Kraft addressed the…

Riley: Japonica, A Mystery to Rhode Islanders—I wanted to check in on a little…

The 10 Greatest Blizzards in Rhode Island History—Which winter storm reigns supreme?

Send GoLocalProv Your Blizzard Juno Photos—Take part in all of the Snowstorm drama…

David Brussat, Dr. Downtown: Hallucinogens in Kennedy Plaza—The “upgraded” Kennedy Plaza reopened last week


NEW:: Kilmartin Says State Will Receive Over $647k from Pfizer Lawsuit

Wednesday, December 12, 2012


Attorney General Peter F. Kilmartin today announced that he and 33 other attorneys general reached a $42.9 million consent judgment with Pfizer, Inc., to resolve allegations that the Company unlawfully promoted its drugs, Zyvox® and Lyrica®. Under the settlement, Rhode Island will receive $647,722.

With today’s announcement, the Office of Attorney General has reached settlements with major pharmaceutical companies for unfair and deceptive practices in promotion and advertising of drugs worth approximately $5.7 million in 2012, which is deposited in the state’s General Fund.

In addition, the Attorney General’s Medicaid Fraud & Patient Abuse Unit has recovered more than $9.5 million from investigations and settlements to Rhode Island’s state/federal Medicaid program paid by pharmaceutical companies.

“Coupled with other recently announced drug settlement cases, the Office has recovered close to $15 million for the State of Rhode Island and its taxpayers,” said Attorney General Kilmartin. “Despite these significant settlements, pharmaceutical companies continue to engage in deceptive practices to benefit their bottom line. So long as big pharma insists on operating in this manner, we will continue to investigate and prosecute companies that break the rules and hold them financially accountable for their actions.”

In the settlement, the states allege that Pfizer engaged in unfair and deceptive practices in its promotion of Zyvox® by making misleading and unsubstantiated superiority claims that broadened the indications for Zyvox®, an antibacterial agent approved to treat certain types of infections, including among other approved indications, nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (“MRSA”) and complicated skin and skin structure infections due to MRSA. Moreover, the settlement alleges that Pfizer engaged in unfair and deceptive practices in promoting Lyrica® for off-label uses.

As part of the consent judgment, Pfizer agreed to reform how it markets and promotes Zyvox® and Lyrica®.

“Patients and doctors must be able to trust the information provided by drug companies,” said Attorney General Kilmartin. “Misleading claims put patient lives in jeopardy, and pharmaceutical corporations’ illegal promotion of drugs for off-label uses will not be tolerated.”


Enjoy this post? Share it with others.